No Data
No Data
Jingfeng Pharmaceutical (000908.SZ) announced first-quarter results, net profit of 3.553 million yuan, an increase of 174.14%
Jingfeng Pharmaceutical (000908.SZ) released its report for the first quarter of 2024. The company's revenue was 1.01...
Jingfeng Pharmaceutical (000908.SZ): The company's stock may be subject to a delisting risk warning
Zhitong Finance App News, Jingfeng Pharmaceutical (000908.SZ) issued an announcement. According to preliminary estimates by the company's finance department, the company's net assets are expected to be negative at the end of 2023. If the company's net assets at the end of the 2023 audited period are negative, according to the relevant provisions of the “Shenzhen Stock Exchange Stock Listing Rules”, the company's stock transactions will be subject to a delisting risk warning after disclosing the 2023 annual report.
Medical beauty stocks fell collectively. Among them, Jiangsu Wuzhong fell to a standstill, Aimeike fell more than 9%, Jingfeng Pharmaceutical fell more than 5%, Huadong Pharmaceutical, Betaini, and Guanhao Biotech fell more than 4%, and Teyi Pharmaceutica
Medical beauty stocks fell collectively. Among them, Jiangsu Wuzhong fell to a standstill, Aimeike fell more than 9%, Jingfeng Pharmaceutical fell more than 5%, Huadong Pharmaceutical, Betaini, and Guanhao Biotech fell more than 4%, and Teyi Pharmaceutical, Shuyu Pingmin, Changshan Pharmaceutical, and Dian Diagnosis fell more than 3%.
A-share changes | Jingfeng Pharmaceutical's decline may be subject to a delisting risk warning
Gelonghui April 1 | Jingfeng Pharmaceutical (000908.SZ) fell to a halt and reported 2.27 yuan, with a market value of less than 2 billion yuan. According to preliminary estimates by the company's finance department, the company's net assets are expected to be negative at the end of 2023. If the company's net assets at the end of the 2023 audited period are negative, according to the relevant provisions of the “Shenzhen Stock Exchange Stock Listing Rules”, the company's stock transactions will be subject to a delisting risk warning after disclosing the 2023 annual report.
Jingfeng Pharmaceutical (000069.SZ): The company's stock may be subject to a delisting risk warning
Jingfeng Pharmaceutical (000069.SZ) issued an announcement. According to preliminary estimates by the company's finance department, the company expects 2023...
The A-share generic drug sector fluctuated higher, and Keyuan Pharmaceutical rose more than 12%
Gelonghui, March 19 | Keyuan Pharmaceutical rose more than 12%, Jingfeng Pharmaceutical rose and stopped before, Asia Pacific Pharmaceutical and Changjiang Health rose more than 9%, and Dorui Pharmaceutical and Kazanlian followed suit.
No Data